CST, 8082S, Phospho-Jak2 (Tyr1008) (D4A8) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying Jak2 (Tyr1007/Tyr1008) phosphate. Validated for Western Blotting,Fluorescent Western. Available in 2 sizes. Highly specific and rigorously validated in-house, Phospho-Jak2 (Tyr1008) (D4A8) Rabbit Monoclonal Antibody (CST #8082) is ready to ship. Product Usage Information Western Blotting: 1:1000 Fluorescent Western: 1:1000 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Fluorescent Western Specificity / Sensitivity Phospho-Jak2 (Tyr1008) (D4A8) Rabbit Monoclonal Antibody recognizes endogenous levels of Jak2 protein only when phosphorylated at Tyr1008. This antibody also reacts with Jak2 when dually phosphorylated at Tyr1007 and Tyr1008. Cross-reactivity was not observed with other Jak family members by western blot. Species Reactivity: Human, Mouse Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Tyr1008 of human Jak2 protein. Background Members of the Janus family of tyrosine kinases (Jak1, Jak2, Jak3, and Tyk2) are activated by ligands binding to a number of associated cytokine receptors (1). Upon cytokine receptor activation, Jak proteins become autophosphorylated and phosphorylate their associated receptors to provide multiple binding sites for signaling proteins. These associated signaling proteins, such as Stats (2), Shc (3), insulin receptor substrates (4), and focal adhesion kinase (FAK) (5), typically contain SH2 or other phospho-tyrosine-binding domains. Jak2 signaling is associated with a number of cytokines, growth factors, and hormones including IL-3, IL-5, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), erythropoietin (EPO), thrombopoietin (TPO) growth hormone, prolactin, and leptin (6-13). The oncogenic potential of Jak2 has been realized though translocations and point mutations resulting in its enhanced, de-regualated kinase activity, making Jak2 a potential therapeutic target. Jak2 gene translocations resulting in fusions with the TEL (TEL-JAK2) and PCM1 (PCM1-JAK2) have been found in leukemia patients (14,15). An activating point mutation in Jak2 resulting in a valine to phenylalanine switch at position 617 (V617F) has been implicated in myeloproliferative disorders including polycythemia vera and essential thrombocythemia (16). Alternate Names JAK-2; JAK2; Janus kinase 2; Janus kinase 2 (a protein tyrosine kinase); JTK10; Tyrosine-protein kinase JAK2 Specification REACTIVITY: H M SENSITIVITY: Endogenous MW (kDa): 125 Source/Isotype: Rabbit IgG